ESDS Software IPO: ₹720 Cr Target, GMP ₹360
ESDS Software IPO financial market data and Grey Market Premium.
Key Highlights
ESDS Software Solution’s IPO aims to raise ₹720 crore, with shares priced at ₹408-₹429. Grey Market Premium reached ₹360. Opens Aug 28, 2026.
ESDS Software Solution is set to raise approximately ₹720 crores through its Mainboard . The offering opens for subscription on August 28, 2026, with shares priced between ₹408 and ₹429 each.
ESDS IPO Details
- : ₹720 crores
- : ₹408 to ₹429 per share
- Market Lot: 34 shares
- Period: August 28, 2026, to September 1, 2026
- Allotment Date: September 2, 2026
- Refunds and Demat Credits: September 3, 2026
- Listing: and by September 4, 2026
Founded in August 2005, ESDS Software Solution operates as an AI-enabled End-to-End IT Service Provider. The company boasts two decades of experience in IT infrastructure management.
Company Offerings & Infrastructure
- Services: Data center, cloud, colocation, managed services, AI infrastructure solutions
- Clients: Government, BFSI institutions, various enterprises
- Data Centers: Five Tier-III facilities across Nashik, Navi Mumbai, Bengaluru, Mohali, and Noida
- Total Area: Over 75,266 sq. ft.
- Proprietary Platform: SWARAJ Cloud, an AI-powered cloud emphasizing data sovereignty and security
The (GMP) for ESDS Software Solution’s IPO has shown fluctuations. On August 29, 2026, the GMP stood at ₹360, indicating an 83.91% gain over the issue price.
Grey Market Premium Snapshot
- August 29, 2026: ₹360 (83.91% gain)
- Peak GMP: ₹365 (August 27)
- Lowest GMP: ₹245 (August 25)
Separately, the Q-Line Biotech SME IPO aimed to secure ₹214.48 crores. This offering was open from May 21 to May 25, 2026, with a price band of ₹326 to ₹343 per share.
Q-Line Biotech Overview
- Issue Size: ₹214.48 crores
- Price Band: ₹326 – ₹343 per share
- Subscription Period: May 21 to May 25, 2026
- Company Focus: Developing, manufacturing, and marketing reagents and consumables for diagnostic healthcare
- Financial Performance: Top-line growth, but inconsistent net profit, including a setback in FY25 and a significant profit in 9M-FY26
- Investment Advice: Deemed fully priced; well-informed investors advised to consider for medium to long term
Both IPOs reflect ongoing activity in public markets, with ESDS targeting a significant mainboard raise and Q-Line Biotech navigating the SME segment.